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Background: Hereditary startle disease is caused by genetic defects in inhibitory glycine receptor and transporter genes.
Results: Loss of function mutations in SLC6A5, with novel mechanisms of action, were identified in 17 individuals with startle
disease.
Conclusion: Recessive mutations in SLC6A5 represent a second major cause of startle disease.
Significance: Genetic screening for startle disease should encompass both presynaptic and postsynaptic causes of disease.
Hereditary hyperekplexia or startle disease is characterized
by an exaggerated startle response, evoked by tactile or auditory
stimuli, leading to hypertonia and apnea episodes. Missense,
nonsense, frameshift, splice site mutations, and large deletions
in the human glycine receptor 1 subunit gene (GLRA1) are the
major known cause of this disorder. However, mutations are
also found in the genes encoding the glycine receptor  subunit
(GLRB) and the presynaptic Na/Cl-dependent glycine trans-
porter GlyT2 (SLC6A5). In this study, systematic DNA sequenc-
ing of SLC6A5 in 93 new unrelated human hyperekplexia
patients revealed20 sequence variants in 17 index cases present-
ing with homozygous or compound heterozygous recessive
inheritance. Five apparently unrelated cases had the truncating
mutation R439X. Genotype-phenotype analysis revealed a high
rate of neonatal apneas and learning difficulties associated with
SLC6A5mutations. From the 20 SLC6A5 sequence variants, we
investigated glycine uptake for 16 novel mutations, confirming
that all were defective in glycine transport. Although the most
common mechanism of disrupting GlyT2 function is protein
truncation, new pathogenic mechanisms included splice site
mutations and missense mutations affecting residues impli-
cated in Cl binding, conformational changes mediated by
extracellular loop 4, and cation- interactions.Detailed electro-
physiology of mutation A275T revealed that this substitution
results in a voltage-sensitive decrease in glycine transport
caused by lower Na affinity. This study firmly establishes the
combination of missense, nonsense, frameshift, and splice site
mutations in theGlyT2 gene as the secondmajor cause of startle
disease.
Startle disease is a rare disorder characterized by evoked epi-
sodes of hypertonia that can have serious consequences,
including sudden infant death from apnea or aspiration pneu-
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monia (1, 2). Although symptoms often diminish during the
first year of life, the exaggerated startle response can persist into
adulthood, leading to unprotected falls (3, 4). Fortunately, star-
tle disease can be treated using clonazepam (4, 5), which poten-
tiates inhibitory GABAA receptor function. An intervention
called theVigevanomaneuver, involving flexing of the head and
limbs toward the trunk, also dissipates and counteracts the
effects of acute hypertonia and apnea episodes (2). Hyperek-
plexia is recognized and detected within specialist neurology
and pediatric centers worldwide (6, 7). Key collaborations
between clinicians and scientists have revealed that the primary
cause of startle disease is defective inhibitory glycinergic trans-
mission. Currently, the major known genetic cause of hyperek-
plexia is missense, nonsense, frameshift, or splice site muta-
tions in the glycine receptor (GlyR)4 1 gene (GLRA1) (8–10),
although largeGLRA1 deletions are also common in patients of
Kurdish descent (11, 12). Rare mutations in the genes encoding
the GlyR  subunit (GLRB) (13, 14) and the synaptic clustering
proteins gephyrin (GPHN) (15) and collybistin (ARHGEF9) (16)
have also been linked to hyperekplexia.
Because many patients do not harbor defects in these genes,
some years ago we began to consider hyperekplexia as a synap-
topathy. This led to the identification of missense, nonsense,
and frameshift mutations in the GlyT2 gene (SLC6A5), encod-
ing a Na/Cl-dependent neurotransmitter transporter that
maintains a high presynaptic pool of glycine at glycinergic syn-
apses (17, 18). Using detailed structure-function analyses, we
demonstrated that GlyT2 mutations disrupted transporter
membrane trafficking, Na, or glycine-binding sites (17). Sub-
sequently, unique GlyT2 mutations were discovered in cattle
and dogs, causing startle disorders with early neonatal lethality
(19, 20). Here, we present the outcomes from an international
screening program targeting SLC6A5 in 93 unrelated hyperek-
plexia probands. This identified 20 recessive SLC6A5 muta-
tions within 17 index cases, of which 19 are novel variants.
These new mutations were characterized using [3H]glycine
uptake assays and molecular modeling. Electrophysiological
characterization of the GlyT2 mutation A275T revealed that
this substitution results in a voltage-sensitive decrease in gly-
cine transport, caused by lower Na binding at depolarized
membrane potentials. Taken together with our recent study on
GLRA1 mutations in startle disease (10), these results suggest
that recessive modes of inheritance are far more common on a
population basis than dominant mutations, explaining the
apparent sporadic nature of this rare disorder.
EXPERIMENTAL PROCEDURES
Patients and Cases—Individuals of either sex with a clinical
diagnosis of hyperekplexia were ascertained by referral from
neurologists, pediatricians, or clinical geneticists from interna-
tional centers. Informed consent and clinical data were
obtained by the referring clinician (local research ethics com-
mittee, the South West Wales Research Ethics Committee).
Ninety-three unrelated index patients were ascertained in this
population study after evaluation by clinical criteria included a
nonhabituating startle response (positive nose tap test), history
of neonatal/infantile hypertonicity, negative results in GLRA1
gene screening by Sanger sequencing and multiplex ligation-
dependent probe amplification (MLPA), and the exclusion of
phenocopies such as startle epilepsy (7).
Molecular Genetics—Exons and intron-exon boundaries of
SLC6A5 were amplified from genomic DNA isolated from
peripheral blood using established primers sets (17). To avoid
allelic dropout, all of the primers were placed in intronic
regions that were devoid of known single-nucleotide polymo-
ryphisms found in theNationalCenter for Biotechnology Infor-
mation data base dbSNP. Following conventional PCR proto-
cols with patient DNA, PCR products were purified with
QIAquick purification kit (Qiagen) and directly sequenced
using BigDye terminators and an ABI3100 automated se-
quencer (Applied Biosystems). Frequency of single-nucleotide
polymoryphisms or mutations was assessed in 400 control
alleles using restriction fragment length polymorphism, if a
suitable restriction enzyme was available, or case:control con-
trast profiles using the Idaho LightScanner platform. In addi-
tion to Sanger sequencing, all DNA samples were screened for
large deletions or insertions in SLC6A5 using a MLPA DNA
detection kit (MRC-Holland).
Mutagenesis and [3H]Glycine Uptake Assays—GlyT2 muta-
tions were introduced into the pRc/CMV-hGlyT2 expression
construct (17) using theQuikChange site-directedmutagenesis
kit (Stratagene), and the complete coding regionwas sequenced
to verify that only the desired mutation had been introduced.
For [3H]glycine uptake assays, HEK293 cells were grown in
minimal essential medium (Earle’s salts) supplemented with
10% (v/v) FCS, 2 mM L-glutamine, and 20 units/ml penicillin/
streptomycin in 5%CO2, 95% air. The cells were plated on poly-
D-lysine-coated 24-wells plates (Nunc), grown to 50% conflu-
ence, and transfected with 1 g of total pRc/CMV-hGlyT2 or
mutant DNAs using Lipofectamine LTX reagent (Invitrogen).
After 24 h, the cells were washed twice with prewarmed buffer
(118 mM NaCl, 1 mM NH2PO4, 26 mM NaHCO3, 1.5 mM
MgSO4, 5 mM KCl, 1.3 mM CaCl2, 20 mM glucose) pre-equili-
brated with 5% CO2, 95% air. After 2 min, the cells were incu-
bated for 5 min in 0.1 Ci/ml [3H]glycine (60 Ci/mmol;
PerkinElmer Life Sciences) at a final concentration of 300 M.
The cells were rinsed twice with ice-cold buffer pre-equili-
brated with 5% CO2, 95% air and then digested in 0.1 M NaOH
for 2 h. The sampleswere used for scintillation counting and for
determination of protein concentration using the Bradford rea-
gent (Bio-Rad). [3H]Glycine uptake was calculated as nmol/
min/mg of protein and expressed as percentages of that in con-
trol cells transfected with the empty expression vector. All
statistical comparisons used an unpaired Student’s t test.
Molecular Modeling—Fold recognition of human GlyT2 was
performed with GenTHREADER (21) and HHPRED (22). The
structure of the bacterial leucine transporter (LeuT) (PDB:
2A65) (23)was identified as the best template (GenTHREADER
p value: 2e-21; HHPred e-value: 0). An alignment between the
human GlyT2 sequence and the LeuT structure was generated
with the program T-coffee, resulting in 26% sequence identity.
Based on this alignment, 50 homology models of human GlyT2
were calculated using MODELLER-9v7 and assessed with the
4 The abbreviations used are: GlyR, glycine receptor; MLPA, multiplex liga-
tion-dependent probe amplification; LeuT, leucine transporter.
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DOPE statistical potential score (24). The model based on the
lowest score (Normalized DOPE Z score:1.162) was selected.
Additional evaluation using the ProSA web server showed that
themodel quality (Z score2.07) fell within a range typically
found for native proteins of similar size (25). Selected nonsyn-
onymous substitutionsweremodeled into theGlyT2 homology
model using the swapaa command in Chimera, using the Dun-
brack backbone-dependent rotamer library (26) and taking into
account the lowest clash score, the highest number of H-bonds,
and the highest rotamer probability.
For modeling the GlyT2 chloride ion-binding site, Cl was
placed into our model at the coordinates of the carboxylate
carbon of the LeuT Glu-290 side chain (27), based on the
assumption that this position may be occupied by Cl in
homologous transporters (27–29). The residues involved in the
coordination of Cl ion are generally conserved within the
SLC6 transporter family. In our model, these are: Tyr-233 in
TM2, Gln-473 and Ser-477 in TM6, Asn-509 and Ser-513 in
TM7, corresponding to Tyr-47, Gln-250, Thr-254, Asn-286,
and Glu-290 in LeuT, respectively. Energy minimization was
carried out on the model with theminimize structure option in
Chimera (using the MMTK method) (30) and the AMBER 94
force field (31), allowingCl to fitmore favorably in the binding
pocket. In the resulting minimized structure, all distances
between Cl and the side chains of the interacting residues are
below 4.5 Å.
Electrophysiological Analysis of GlyT2 Mutant A275T—
CappedmRNAswere transcribed from linearized cDNAs using
the T7 mMessage mMachine kit (Ambion, Austin, TX), and 50
ng of mRNAs were microinjected in Xenopus oocytes prepared
and maintained as described (32). For nuclear injection exper-
iments, 30 ng of each plasmid DNA was microinjected into the
animal pole of multiple oocytes. 3–7 days later, whole cell cur-
rents were recorded in oocytes held at 40 mV with a two-
electrode voltage clamp amplifier (Warner OC-725C; Harvard
Apparatus,Holliston,MA) computer interfacedwith aDigidata
1320A and pClamp 8 software (MDSAnalytical Technologies).
Steady-state currents were low pass filtered at 10 Hz and digi-
tized at 100 Hz, whereas currents recorded using voltage step
were filtered at 1 kHz and digitized at 5 kHz. Current and volt-
age electrodes were filled with 3 M KCl solution and had typical
resistance of 1 MOhm. The oocytes were continuously bathed
with a solution containing 100 mM NaCl, 1.8 mM CaCl2, 1 mM
MgCl2, 5 mM Hepes, pH 7.2, adjusted with KOH. Salt and
glycine were from Sigma. The selective GlyT2 inhibitor
ORG25543 was a generous gift from Organon.
RESULTS
Mutation Analysis of SLC6A5 in Hyperekplexia—A total of
93 index cases were screened for genetic variation in SLC6A5
coding exons and donor and acceptor splice junctions by
Sanger DNA sequencing (17). Sequence variants were
assigned as potential disease-causing mutations after exclu-
sion from a panel of 400 human controls and cross-referenc-
ing with common SLC6A5 polymorphisms (17) and those
found in dbSNP (supplemental Table S1). This revealed 20
sequence variants that were exclusive to 17 index cases, of
which the vastmajority (14 of 17) showed homozygous or com-
pound heterozygous recessive inheritance (Fig. 1 and Table 1).
These variants included four nonsense mutations (W151X,
R191X, Y297X, and R439X), four frameshift mutations
(P108Lfs25, L198Rfs123, S489Ffs39, and I665Kfs1),
and three splice site mutations (IVS141G, IVS131 GT,
and IVS81 GA). Novel missense mutations affected resi-
dues in TM2 (L237P, P243T, and E248K), TM3 (A275T), TM7
(S513I), the extracellular TM7-TM8 loop (F547S), and the
intracellular TM10-TM11 loop (Y656H and G657A). In three
cases (case 12, W151X; case 13, R439X; and case 14, A275T),
only a single defective SLC6A5 allele was detected. Notably, in
case 13, the mutation detected (C1315T, resulting in R439X) is
also found in the homozygous state in cases 4–6. This sug-
gested that a second inactivating mutation might remain to be
detected in these cases. However, we were unable to detect
deletions of one or more SLC6A5 exons in these individuals
using MLPA.
Truncating nonsense or frameshift mutations distributed
throughout the GlyT2 coding region were found in 11 of 20
patients (Fig. 1 and Table 1). As well as loss of function via
protein truncation, these mutations also have the potential to
lead to nonsense-mediated RNA decay (33). We also identified
a common nonsense mutation, C1315T, resulting in R439X,
which was detected in several apparently unrelated cases from
different ethnic backgrounds (Caucasian andPakistani origins).
Splice sitemutations were identified in cases 1 (IVS141G), 7
(IVS131 GT), and 9 (IVS81 GA), all affecting the 1
position (albeit in different introns). This means that the first
nucleotide in the corresponding intron (i.e., part of the splice
donor site consensus gt) is deleted or substituted. These
changes are predicted to result in either mis-splicing or intron
retention. Genotype-phenotype analysis revealed that all
patients harboring mutations in SLC6A5 presented with
classical hyperekplexia symptoms (supplemental Table S2)
including neonatal muscle hypertonia and an exaggerated
startle response to tactile or acoustic stimuli with preserva-
tion of consciousness. However, hyperekplexia caused by
SLC6A5 mutations was also associated with high rates of
recurrent neonatal apneas, learning difficulties, and devel-
opmental delay. There were frequent reports of speech delay
in excess of motor delay, with subsequent catch-up in many.
This seems unlikely to be due to the effect of benzodiaz-
epines, because the vast majority of children received pro-
found benefit from their administration.
Functional Analysis of GlyT2 Variants Using 3H[Glycine]
Uptake—To confirm the effects of GlyT2 mutations on glycine
uptake, we tested the capacity of recombinantly expressed
human GlyT2 and selected mutants produced by site-directed
mutagenesis to mediate the uptake of [3H]glycine. GlyT2
harboring nonsense (W151X, R191X, Y297X, and R439X),
frameshift (P108Lfs25, L198Rfs123, S489Ffs39, and
I665Kfs1) and missense (L237P, P243T, S513I, F547S,
Y656H, and G657A) mutations revealed no significant [3H]gly-
cine uptake inHEK293 cells compared with control values (Fig.
2a). By contrast, the A275T mutant was capable of [3H]glycine
uptake, although at a lower level thanwild-typeGlyT2. Because
mutant E248K caused substantial cell death in transfected
HEK293 cells, we assessed the function of GlyT2 E248K by
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nuclear injection inXenopus oocytes (Fig. 2b). Unlike wild-type
GlyT2 andGlyT2A275T,GlyT2E248Kwas unable to direct the
formation of functional glycine transporters in this system,
confirming loss of function for this mutant. Taken together,
these results provide strong evidence for a bi-allelic loss of
GlyT2 function in individuals 1–11 and 15–17. However, the
pathogenic mechanisms underlying the clinical phenotype in
patients 12 (heterozygous for W151X), 13 (heterozygous for
R439X), and 14 (heterozygous for A275T) remained ambigu-
ous. We therefore tested whether co-transfection of the two
alleles would provide evidence for dominant effects, because
complex-glycosylated GlyT2 forms dimers located at the cell
surface (34). However, mixing W151X, A275T, or R439X with
wild-type hGlyT2 in a 1:1 ratio did not substantially alter
[3H]glycine uptake (Fig. 2c), suggesting that W151X, A275T,
and R439X do not function in a dominant-negative manner in
vitro.
Molecular Modeling of GlyT2 Mutations—To gain further
insight into the precise molecular mechanisms underlying
GlyT2 missense mutations, we examined each mutation indi-
vidually and in the context of a homology model of human
GlyT2 constructed using the crystal structure of the bacterial
leucine transporter LeuT (Fig. 3a). Alignment of the Aquifex
aeolicus LeuT with GlyT1 and GlyT2 also allowed residues
potentially involved in coordinating glycine or Na and Cl
binding to be identified. Three new missense mutations result
in substitution of residues in TM2 (L237P, P243T, and E248K).
Introduction (L237P) or elimination (P243T) of proline resi-
dues in transmembrane helices is predicted to have a significant
effect on local structural rigidity, destabilizing the native fold,
which often results in accelerated degradation or aggregation of
the mutant protein (35). By contrast, substitution E248K in
TM2 results in the replacement of a negatively charged gluta-
mate residue for a positively charged lysine, with a longer side
chain that introduces potential clashes with Ala-480 and Ala-
481 in TM6 (Fig. 3, b and c), whichmay affect the orientation of
the key glycine-binding residue Trp-482.
Substitution A275T in TM3 results in predicted clashes with
Ile-279, which may alter the orientation of the predicted gly-
cine-binding residue Tyr-287 further along TM3 (Fig. 3, d and
e). The corresponding residue in LeuT (Tyr-108) not only
anchors the leucine substrate but also stabilizes the unwound
FIGURE 1. Human GlyT2 mutations identified in individuals with startle disease. The amino acid sequence of human GlyT2 indicating the positions of
putative transmembrane (TM) domains (colored boxes) and amino acid residues affected by hyperekplexiamutations; this study and Refs. 20–22). Blue and red
triangles indicate residues in hGlyT2 that are likely to coordinate Na and Cl ions, respectively, based on structure/function studies of the bacterial leucine
transporter LeuT andothermammalian neurotransmitter transporters such asGAT-1 and SERT. However, GlyT2 binds threeNa ions, whereas LeuTbinds two,
suggesting that other residues involved in Na coordination remain to be identified. Filled black circles indicate residues predicted to be involved in glycine
binding.
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region of TM1 (36) by binding the amide nitrogen of Leu-25,
equivalent to Leu-211 in GlyT2. Thus, A275T could destabilize
the unwound region of TM1, which contains several determi-
nants of glycine and Na binding. By contrast, substitution
S513I in TM7 introduces a much larger side chain at this posi-
tion, resulting in predicted clashes with Asn-213 (TM1) and
Asn-509 (TM7), both of which are involved in Na binding
(Fig. 3, f and g). It is also noteworthy that the recent discovery
(27–29) of residues involved in Cl binding in GAT-1 and
SERT suggests that residues Tyr-233 (TM2), Gln-473, and Ser-
477 (TM6) together with Asn-509 and Ser-513 (TM7) are likely
to perform equivalent roles in GlyT2 (Fig. 4a). Substitution
S513I in TM7 introduces a larger side chain (Fig. 4b), which
lacks the hydroxyl necessary for the coordination of the Cl ion
and may prevent Cl binding. Because a hydroxyl at this rela-
tive position is highly conserved in SLC6 transporters (27–29),
the S513I substitution is predicted to interfere with glycine
transport by disrupting the both Cl (directly) and Na (indi-
rectly) interactions.
Substitution F547S affects a highly conserved residue found
in extracellular TM7-TM8 loop 4B (EL4B). EL4B is composed
of two short helices separated by an acute bend and participates
in conformational mobility during the transport cycle in DAT
(37), GAT-1 (38), GlyT1 (39), and SERT (40). Lastly, substitu-
tion Y656H in the intracellular TM10-TM11 loop is predicted
to abolish a cation- interaction that exists between Tyr-656
and Arg-660 (Fig. 3, h and i). This interaction is likely to have a
significant role in the folding or stabilization of the protein in
this unwound region or interfere with important intracellular
GlyT2 accessory protein interactions, because a neighboring
residue was substituted (G657A) in another individual.
Electrophysiological Analysis of the Single-hit GlyT2 Mutant
A275T—To obtain further insights into the transport proper-
ties of the only partially functional GlyT2 mutant A275T, we
performed a detailed electrophysiological characterization of
the charge movement and steady-state kinetics of the A275T
mutant expressed inXenopus oocytes using two-electrode volt-
age clamp methodology (32, 41). In the absence of glycine,
TABLE 1
Details of SLC6A5 hyperekplexia mutations identified in this study
The modes of inheritance are as follows: NC, not confirmed; CH, compound
heterozygosity; AR, autosomal recessive. Homozygous recessive inheritance, i.e.,
the same allele inherited from both parents, is indicated by (H). For compound
heterozygosity, (P) indicates paternal allele, and (M) indicates maternal allele. ,
deletion.
Case Mode Exon Genotype Consequences Class
1 AR 14 IVS14 1 G (H) Impact on splicing Splice site
2a AR 4 C727A (H) P243T Missense
3a AR 5 C891A (H) Y297X Nonsense
4 AR 8 C1315T (H) R439X Nonsense
5 AR 8 C1315T (H) R439X Nonsense
6 AR 8 C1315T (H) R439X Nonsense
7 CH 8 C1315T (P) R439X Nonsense
13 IVS13 1 GT (M) Impact on splicing Splice site
8b CH 11 T1640C (M) F547S Missense
13 T1966Cb Y656H Missense
9a CH 4 G742A (P) E248K Missense
8 IVS8 1 GA (M) Impact on splicing Splice site
10c NC 9 CT [1460–1467] S489F fs39 Frameshift 
14 G1970C G657A Missense
11a CH 3 C571T (P) R191X Nonsense
3 TG [593–594] (M) L198R fs123 Frameshift 
12 NC 2 G452A (P) W151X Nonsense
13 NC 8 C1315T (P) R439X Nonsense
14 NC 5 G823A (P) A275T Missense
15 CH 2 C [319–323] (P) P108L fs25 Frameshift 
14 T [1994] (M) I665K fs1 Frameshift 
16 CH 3 TG [593–594] (P) L198R fs123 Frameshift 
4 T710C (M) L237P Missense
17 AR 10 G1538T (H) S513I Missense
a Affected sibling with the same mutation(s).
bOnly one parent was available to assess compound heterozygote status; here, the
maternal allele did not carry the Y656H mutation.
c Parental samples were lost to contact, and long range PCR attempts were unsuc-
cessful (22-kb target).
FIGURE 2. Functional activity of hGlyT2 and hyperekplexia mutants.
a, glycine uptake in HEK293 cells transiently expressing hGlyT2 and single
hyperekplexia mutants after 5 min of incubation with [3H]glycine (60
Ci/mmol; PerkinElmer Life Sciences) at a final concentration of 300 M.
Because low levels of glycine uptake are found in HEK293 cells (17), [3H]gly-
cine uptakewas calculated as nmol/min/mgof protein and then expressed as
a percentage of the empty expression vector transfected control. Only wild-
type GlyT2 and mutant A275T result in any detectable uptake above control
values. b, steady-state amplitude of the current evoked by 1 mM glycine at
70 mV in Xenopus oocytes injected with selected GlyT2 expression cDNAs.
Because 1mMglycine evokes a small inward current of 1.10.34nA (n8) in
non-injected (NI) oocytes (because of endogenous amino acid transporters),
the threshold for heterologous expression of GlyT2 was set at5 S.D. (2.8
nA, dashed line). Robust currents were observed for 10 of 14 oocytes injected
withwild-typeGlyT2 and12of 18 oocytes injectedwith theA275Tmutant. By
contrast, neither E248K or S513I mutants exhibited currents above this
threshold (n 15 and 9, respectively). c, selected [3H]glycine uptake experi-
ments for mutations W151X, A275T, and R439X. We noted no significant
effect of co-expressing these mutants with wild-type GlyT2, suggesting that
these mutations do not show dominant-negative effects. The data are the
means  S.E. (n  4–12). Statistical comparisons were made using an
unpaired Students t test. For a, the asterisk indicates significantly different
from empty vector control. p 0.01.
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membrane expression of GlyT2 A275T induced Na-depen-
dent transient currents in response to voltage jumps. These
transient currents were sensitive to glycine and the selective
GlyT2 inhibitor ORG25543. The maximal charge movement
was proportional to the maximal amplitude of glycine-evoked
steady-state inward currents (Fig. 5, a and b). Current-voltage
(I-V) relationships for different glycine concentrations showed
no reversal potential, indicating that tight glycine coupling was
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preserved in A275T (Fig. 5c), although the dose-response curve
showed amarked increase in voltage dependence of the glycine
(EC50) and the maximal current (Imax; Fig. 5, d–f). Because gly-
cine is electrically neutral, an increase in the EC50 voltage
dependence of theA275Tmutant suggests that, in linewith our
molecular modeling prediction, the allosteric interaction
between Na and glycine binding may be compromised, par-
ticularly at depolarizing potentials. Indeed, the relative trans-
port efficacy (Imax/EC50) of the A275T versus wild-type GlyT2
decreased from 101.3% at 100 mV to 21% at 0 mV (Fig. 5g). To
further examine Na interactions for the A275T mutant, we
compared the kinetics and charge distribution of wild-type
GlyT2 andA275T transient currents isolated in the presence of
10MORG25543 (Fig. 6a). On average, the membrane expres-
sion of A275T in different batches of oocytes was lower than for
wild-type GlyT2 as suggested by the lower maximal charge dis-
tribution (Qmax) for A275T (10  0.84 nC, n  19) than for
wild-typeGlyT2 (20.6 2.4 nC, n 14). To assessNa binding
to the A275Tmutant, wemeasured z, a sensitive parameter of
the Boltzmann equation used to fit the distribution of the
charge movement associated with the transition between the
Na-bound and Na-unbound conformations of the trans-
porter (42). Although the equivalent charge (z) associatedwith
the charge movement was unchanged in A275T (1.19  0.02,
n  19, versus 1.21  0.02 for wild-type GlyT2, n  14), sug-
gesting similar ionic coupling for wild-type GlyT2 and A275T,
the half-distribution potential (V0.5) was shifted to a negative
potential by40 mV from27.5 1.8 mV (wild-type GlyT2,
n  14) to 67.4  1.44 mV (A275T, n  19; Fig. 6, b and c).
This indicates a decrease in the apparent Na affinity for the
A275T mutant. Further evidence supporting this finding was
provided by the faster kinetics of the off transient currents for
A275T during repolarization at 40mV (w  10.6  0.5 ms,
n 15) than for wild-typeGlyT2 (w 19.5 1.45ms, n 10).
DISCUSSION
Our study represents the largest multicenter screening study
for GlyT2 mutations in hyperekplexia to date, encompassing
genotype-phenotype correlations, functional tests of GlyT2
mutants, molecular modeling, and electrophysiology. Our
ongoing genetic screening program, which has accrued 230
index cases over the last 18 years (7), has identified an addi-
tional 20 mutations in the GlyT2 gene (SLC6A5) in 14 index
cases showing homozygous or compound heterozygous reces-
sive inheritance in 93 recently submitted samples (2006–2010).
For the remaining three cases, we only identified a single defec-
tive allele but excluded allelic dropout and large deletions using
MLPA. Although co-expression of the three mutants (W151X,
A275T, and R439X) with wild-type GlyT2 did not reveal any
dominant-negative effects in an in vitro [3H]glycine uptake
assay, it is noteworthy that for the individual harboring the
paternal A275T allele, startle was also observed in the father
(supplemental Table S2), suggesting that a dominant effectmay
be present in vivo. However, inheritance of a single defective
SLC6A5 allele (Y377X) has been observed in another study (18),
so another possibility is that a secondmutation in a promoter or
regulatory element could explain cases 12 and 13 (Table 1).
However, because the current minimal SLC6A5 promoter
encompasses90 kb upstream of exon 1 and regulatory motifs
remain uncharacterized (43), it is not currently straightforward
FIGURE 3.Molecular modeling of GlyT2mutations. a, side view of the human GlyT2 monomer showing transmembrane helices as colored ribbons. Glycine
and two (of three) sodium ions (purple spheres) are depicted. Note that the TM3-TM4 extracellular loop (EL2) was not modeled because of an insertion of
residues 312–354 in GlyT2 relative to LeuTAA. b and c, substitution E248K in TM2 replaces a negatively charged glutamate for a positively charged lysine, with
a longer side chain that introduces potential clashes (red lines) with Ala-480 andAla-481 in TM6. This is likely to affect the orientation of the key glycine-binding
residue Trp-482. d and e, substitution A275T in TM3 results in several predicted clashes with Ile-279 that are predicted to alter the orientation of the potential
glycine-binding residue Tyr-287 and destabilize the unwound region of TM1, which contains several determinants of glycine and Na binding. f and g,
substitution S513I in TM7 introduces a larger side chain at this position, resulting in predicted clasheswithAsn-213 (TM1) andAsn-509 (TM7), both ofwhich are
involved in the binding of Na. Note that Asn-509 and Ser-513 are also predicted to be involved in coordinating Cl binding to GlyT2. h and i, substitution
Y656H in the intracellular TM10-TM11 loop is predicted to abolish a cation- interaction that exists between Tyr-656 and Arg-660 that may affect folding or
stability or interfere with intracellular GlyT2 accessory protein interactions.
FIGURE 4.Molecularmodelingof theGlyT2 chloride ion-binding site. a, exploded viewof the humanGlyT2 chloride ionbinding site showingCl as a green
sphere and coordination by Tyr-233 in TM2, Gln-473 and Ser-477 in TM6, and Asn-509 and Ser-513 in TM7. b, substitution S513I in TM7 introduces a larger side
chain, which lacks the essential hydroxyl necessary for the coordination of Cl andmay occlude the binding site. Because a hydroxyl at this position is highly
conserved in SLC6 transporters (27–29), this substitution is likely to disrupt glycine uptake by directly interfering with coordination of Cl.
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to address this possibility. Another plausible explanation is that
these two cases may represent the first examples of digenic
hyperekplexia, where single mutations in two unlinked genes
are present in a single individual, and the combination of the
two genetic lesions causes a disease phenotype that is not
apparent in individuals harboring only one of these mutations.
Despite this caveat, our study effectively triples the number
of known cases with SLC6A5 mutations, firmly establishing
mutation in the GlyT2 gene as a second major cause of startle
disease. Taken together with our recent study of mutations in
the GlyR 1 subunit gene (GLRA1) (10), it is now apparent that
recessive hyperekplexia is far more common on a population
FIGURE 5. Current-voltage relationships and dose-response curves for the GlyT2mutant A275T. a, current traces evoked by 500-ms voltage steps from
50mV to140mV by decrements of 10mV in representative oocytes expressing wild-type GlyT2 (upper panels) and the GlyT2 A275Tmutant (lower panels)
in control solution (left traces) or in the presence of glycine (right traces). b, plots of current amplitude evoked by glycine (1 mM) at 40 mV and Qmax (see
“Experimental Procedures” and Fig. 6) relationship for oocytes expressing wild-type GlyT2 (upper panel) or GlyT2 A275T (lower panel). The solid lines show the
linear regressionwith a slopeof 15.9 s1 (r20.773,n20) and24.1 s1 (r20.774,n14) forwild-typeGlyT2andA275T, respectively. c, voltagedependence
of steady-state currents evoked by the glycine concentrations indicated at left in a representative oocyte expressing GlyT2 A275T. d, dose-response curves of
the glycine-evoked current at the membrane potentials indicated on right in the same oocytes as in c. The solid lines are the least square fit of the data to the
Hill equation: Igly Imax/(1 EC50/[gly])
n. e, effect ofmembrane potential on glycine EC50 for oocytes expressing GlyT2 A275T (red circles, n 8) andwild-type
GlyT2 (green circles, n 7). The solid lines correspond to the fit of the data to the equation EC50 A B
uVm, where A 23.7 and 29M, B 62.1 and 379M,
and   1.4 and 1.34 for wild-type GlyT2 and A275T, respectively, where u  F/RT (R is the universal gas constant, T is the absolute temperature, and F is
Faraday’s constant). f, voltage dependence of Imax for wild-type GlyT2 (n 8) and A275T (n 7). Imax values were normalized by the values at 0 mV. The solid
lines correspond to the fit of the data to the equation Imaxe
uVm, with  0.3 and 0.22 for wild-type GlyT2 and A275T, respectively. g, relative efficacy
(Imax/EC50) of A275T/wild-type GlyT2.
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basis than dominant hyperekplexia, which received initial
attention because of the characterization of extended families
(8, 9) harboring dominantGLRA1mutations such as R271Q/L.
In commonwith previous studies (17, 18), genotype-phenotype
analysis revealed that GlyT2 mutations in humans are not as
severe as those observed in mice, dogs, and cattle, where muta-
tions in SLC6A5 cause extreme muscle rigidity, tremor, diffi-
culty in breathing, and earlymortality (19, 20, 44).However, it is
noteworthy that therapeutic interventions are rarely applied in
animals with startle disease, because this condition is often only
recognized post mortem.
In humans, it is clear that SLC6A5mutations result in more
severe clinical signs thanmutations inGLRA1. In particular, the
majority (over 90%) of children with SLC6A5-linked hyperek-
plexia have recurrent neonatal apneas. This may explain the
clinical and parental anxiety surrounding hyperekplexia and
could underlie a small but discernible increase inmortality rate.
Whether the increased rate of specific measures of develop-
mental delay (such as late motor milestones) or learning dis-
ability is due to these apnea attacks is hard to prove. Because
almost all children with SLC6A5-linked hyperekplexia have
apneic attacks (and the number or severity of the attacks are not
recorded), we cannot explain why nearly half the patients did
nothave any developmental or cognitive issues. Another poten-
tial explanation for these differences is that defective presynap-
tic glycine uptake is predicted to affect the function of multiple
GlyR subtypes, i.e., 2 and 3, as well as the predominant
1 isoform. In this regard, it is noteworthy that GlyR 3
knock-out mice were recently shown to have an irregular res-
piratory rhythm (45).
Ourmolecularmodeling and [3H]glycine uptake studies have
revealed the existence of several new pathogenic mechanisms
that result in defective glycine transport. Previously known
mechanisms included truncation of the GlyT2 polypeptide
caused by nonsense and frameshiftmutations (17, 18), to which
we can now add splice site mutations that likely result in either
exon skipping on intron retention (cases 1, 7, and 9; Table 1).
Previous pathogenic mechanisms reported for missense muta-
tions (17) that resulted in apparently normal membrane traf-
ficking included defects in glycine (W482R in TM6) or Na
binding (N509S in TM7). With the exception of S513I in TM7,
the new missense substitutions reported in this study (L237P,
P243T, E248K, A275T, F547S, Y656H, and G657A) do not
directly affect predicted Na-, Cl-, or glycine-binding resi-
dues (Fig. 1). However, homology modeling of human GlyT2
based on the structure of the bacterial leucine transporter LeuT
(23) and analysis of key structure-function studies of related
transporters has allowed us to suggest several hypothetical
pathogenic mechanisms for hyperekplexia mutations. These
includemutations that are predicted to: (i) affect the conforma-
tion of TM2 (L237P, P243T); (ii) indirectly affect glycine
(A275T and E248K) or Na (A275T and S513I) binding; (iii)
directly affect Cl binding (S513I); (iv) affect the conforma-
tional mobility of EL4 (F547S); and (v) affect cation- or acces-
sory protein interactions with the intracellular TM10-TM11
loop (Y656H and G657A). Although these mechanisms are all
FIGURE6.Pre-steady-statekineticsof theGlyT2mutantA275T.a, relaxation currents recorded in representativeoocytes expressingwild-typeGlyT2 (green)
or GlyT2 A275T (red) during the repolarization to the holding potential (40 mV) after 400-ms step pulses from50 to140 mV. Currents recorded in the
presence ofORG25543were subtracted. b, time integral of the relaxation currents for oocytes expressingwild-typeGlyT2 (green circles, n 14) or GlyT2-A275T
(red circles, n 19). The solid lines are the least square fit of the data to the Boltzmann equation: (QV Qmin)/Qmax 1/(1 e
zu(V0.5Vm)) c, box plots of Qmax,
V0.5, z, and weighted distributions for oocytes expressingwild-type GlyT2 (green, n 14) or GlyT2 A275T (red, n 19). The box edges represent the 25th and
75th percentiles with themedian line. The errors bars represent the 10th and 90th percentiles.
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of intrinsic interest, our study confirms that the Cl-binding
residue Ser-513 in GlyT2 (equivalent to Ser-372 in SERT and
Ser-331 in GAT-1) has a key functional role in glycine uptake.
Replacement of Ser-372 in SERT with glutamate (S372E) or
aspartate (S372D) results in Cl-insensitive transporters with
lowuptake activity. However, consistentwith our findings, sub-
stitution S372L completely abolished serotonin uptake (28),
suggesting that either a Cl ion or a carboxylate side chain as in
LeuT is required in this area for the normal uptake cycle.
Lastly, our detailed electrophysiological characterization of
theA275Tmutation demonstrated that thismutation results in
an increase in glycine EC50 at depolarizing potentials that
reduces the ability of the transporter to pump glycine at low
concentrations, a situation that prevails at the synaptic cleft. In
addition, lower membrane expression of A275T may also
reduce glycine uptake below the level required for supplying
glycine in axons for maintaining adequate vesicle refilling (46).
In line with our molecular modeling predictions, alterations in
glycine uptake in A275T are primarily linked to a decrease in
the affinity of Na binding with the apo-transporter as indi-
cated by the leftward shift in the potential of half distribution.
The Boltzmann distribution of charge movement indicated
that the fraction of transporter bound with Na will decrease
by a factor of2 compared with wild-type GlyT2 at a negative
potential of60mV (0.42 and 0.82, respectively). Because gly-
cine affinity is Na-dependent (41), this difference in the frac-
tion ofNa-bound transporter suggests that 50%ofA275Tmay
not be able to capture synaptically released glycine, thus reduc-
ing the local recycling that is required for the replenishment of
vesicular transmitter levels (46).
Although sequential genetic analysis of our cohort of hyper-
ekplexia DNAs has revealed many additional mutations in
GLRA1 and SLC6A5, a high proportion of index cases (65%)
remain mutation-negative for these major genes of effect. This
suggests that other hyperekplexia/startle disease genes exist or
that a number of different mutations remain to be character-
ized in regulatory elements at existing loci, e.g., upstream pro-
moters. There are certainly precedents for extensive genetic
heterogeneity in other neurological disorders. For example,
mutations in both inhibitory GABAA receptor and voltage-
gated Na channel genes are associated with generalized epi-
lepsy with febrile seizures plus (GEFS). Future challenges are
to: (i) understand the regulatory elements controlling tran-
scription ofGLRA1,GLRB, and SLC6A5 and (ii) use alternative
disease gene discovery techniques, such as array comparative
genomic hybridization and exome/genome sequencing to
search for pathogenic mutations in novel startle disease genes.
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